Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 10, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Present at the 2022 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PDTM) and Related Neurological Disorders

TORONTO, Ontario and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
March 02, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences’ PMN310 antibody demonstrates significant cognitive benefit in a mouse model of Alzheimer’s disease

TORONTO, Ontario and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
February 03, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Renowned Neuroscientists, Dr. Guy Rouleau and Dr. Alain Dagher to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass. , Feb. 03, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
January 27, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Appoints Internationally Recognized Neuroscientist Dr. Cheryl Wellington to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development...
January 18, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Announces Antibody Program for Schizophrenia Therapy and Recruitment of Dr. Carsten Korth to its Scientific Advisory Board

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 18, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
January 07, 2022 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in the Biotech Showcase 2022 Virtual Panel Discussion: Aduhelm Stimulating the Next Generation of Alzheimer’s Treatment

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
January 06, 2022 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences to Participate in H.C. Wainwright BioConnect 2022 Virtual Conference

TORONTO, Ontario and CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
December 16, 2021 07:30 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Issues Chairman’s Memorandum

TORONTO, Ontario and CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of...
December 02, 2021 07:00 ET | Source: ProMIS Neurosciences Inc.

ProMIS Neurosciences Shareholders Approve Special Resolution

TORONTO and CAMBRIDGE, Mass., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (the “Company”), a biotechnology company focused on the discovery and development...
November 17, 2021 07:00 ET | Source: ProMIS Neurosciences Inc.

A Second Independent Proxy Advisor, ISS, Recommends Promis Neurosciences Shareholders Vote for the Share Consolidation

For any questions, please contact ProMIS’ proxy solicitation agent, Laurel Hill Advisory Group at 1-877- 452-7184 (+1-416-304-0211 outside North America) or email assistance@laurelhill.com. ...